NCT07254871

Study of DM-101PX in Adults With Birch Pollen Allergy

A Phase 2, Randomized, Double-Blind, Placebo-controlled Study to Investigate the Safety and Efficacy in Reducing Nasal Allergen Challenge Provoked Symptoms of Treatment With DM-101PX in Adults With Birch Pollen Allergic Rhinitis or Rhinoconjunctivitis

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Desentum Oy · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults. Expanded access to the study treatment is not available.

Detailed description

The study will be carried out in two study sites located in Canada

Conditions

• Birch Pollen Allergy

Interventions

Type	Name	Description
BIOLOGICAL	DM-101PX	subcutaneous injection of DM-101PX
BIOLOGICAL	Placebo	Placebo to match DM-101PX administered subcutaneously

Timeline

• Start date: 2025-09-26
• Primary completion: 2026-04-30
• Completion: 2026-08-31
• First posted: 2025-11-28
• Last updated: 2026-01-21

Locations

1 site across 1 country: Canada